Grand Rapids, MINCT03719105Now EnrollingIRB Ready

NK-Cell Lymphoma Clinical Trial in Grand Rapids, MI

Access cutting-edge nk-cell lymphoma treatment through this clinical trial at a research site in Grand Rapids. Study-provided care at no cost to qualified participants.

Sponsored by New York Medical College

Quick Self-Assessment

See if you qualify for this Grand Rapids location

Preparing your pre-screening questions…

Expert Care in Grand Rapids

Access nk-cell lymphoma specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related nk-cell lymphoma treatment provided free

Apply for This Grand Rapids Location

Check if you qualify for this nk-cell lymphoma clinical trial in Grand Rapids, MI

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Grand Rapids

    Convenient for MI residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Grand Rapids site if eligible
  4. 4Begin participation

About This NK-Cell Lymphoma Study in Grand Rapids

Patients are in 2 cohorts: Cohort 1: dexamethasone, methotrexate, ifosfamide, pegaspargase, and etoposide (modified SMILE) chemotherapy regimen alone and pembrolizumab in children, adolescents, and young adults with advanced stage NK lymphoma and leukemia Cohort 2: combining pralatrexate (PRX) (Cycles 1, 2, 4, 6) and brentuximab vedotin (BV) (Cycles 3, 5) to cyclophosphamide, doxorubicin, and prednisone in children, adolescent, and young adults with advanced peripheral T-cell lymphoma (non-anaplastic large cell lymphoma or non-NK lymphoma/leukemia) . Both groups proceed to allogeneic stem cell transplant with disease response.

Sponsor: New York Medical College

Who Can Participate

Inclusion Criteria

Patients must weigh at least 10 kilograms at the time of the study enrollment.
Diagnosis Newly diagnosed patients with histologically proven mature T- and NK- cell neoplasms: COHORT 1
Aggressive NK cell leukemia (ICD-O code 9948/3)
Extranodal NK/T-cell lymphoma, nasal type (ICD-O code 9719/3) COHORT 2
Enteropathy-associated T-cell lymphoma (ICD-O code 9717/3)
Hepatosplenic T-cell lymphoma (ICD-O code 9716/3)
Peripheral T-cell lymphoma, non-otherwise specified (ICD-O code 9702/3)
Angioimmunoblastic T-cell lymphoma (ICD-O code 9705/3)
Other mature T- and NK-cell neoplasm histologies will considered after case-by-case discussion with Study Chairs and executive Vice-Chair Patients with lymphoma must have stage III or IV disease (See Appendix III for Staging).
Organ Function Requirements Adequate liver function defined as:
Total bilirubin ≤ 1.5 x upper limit of normal (ULN) for age.
ALT (SGPT) \< 3 x ULN for age. Adequate cardiac function defined as:
Shortening fraction of ≥ 27% by echocardiogram, or
Ejection fraction of ≥ 50% by radionuclide angiogram. Adequate pulmonary function defined as: • Patients with a history of pulmonary dysfunction must have no evidence of dyspnea at rest, no exercise intolerance due to pulmonary insufficiency, and a pulse oximetry \> 92% while breathing room air unless current dysfunction is due to the lymphoma, in which case the patient is eligible.

Exclusion Criteria

Alk+ or Alk- Anaplastic Large Cell Lymphoma (ALCL)
Patients with active CNS disease.
Patients with stage I or stage II disease (See Appendix III for Staging).
Patients who have received any prior cytotoxic chemotherapy for the current diagnosis of NHL.
Previous steroid treatment and/or radiation treatment are not allowed unless they are used for emergency management. Patients who have received emergency irradiation and/or steroid therapy will be eligible only if started on protocol therapy not more than one week from the start of radiotherapy or steroids.
Female patients who are pregnant. Pregnancy tests must be obtained in girls who are post menarchal.
Lactating females, unless they have agreed not to breastfeed their infants.
Patients with Down syndrome.
Patients taking CYP3A4 substrates with narrow therapeutic indices. Patients (COHORT 2 ONLY) chronically receiving medications known to be metabolized by CYP3A4 and with narrow therapeutic indices (See Appendix V). The topical use of these medications (if applicable) is allowed.
Patients taking CYP3A4 inhibitors. Patients (COHORT 2 ONLY) chronically receiving drugs that are known potent CYP3A4 inhibitors within 7 days prior to study enrollment (See Appendix V). The topical use of these medications (if applicable) is allowed.
Patients taking CYP3A4 inducers. Patients (COHORT 2 ONLY) chronically receiving drugs that are known potent CYP3A4 inducers within 12 days prior to study enrollment (See Appendix V).

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Grand Rapids?

Yes, this clinical trial (NCT03719105) has an active research site in Grand Rapids, MI that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

NK-Cell Lymphoma Treatment Options in Grand Rapids, MI

If you're searching for nk-cell lymphoma treatment options in Grand Rapids, MI, this clinical trial (NCT03719105) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Grand Rapids research site is actively enrolling participants for this clinical trial. You'll receive care from experienced nk-cell lymphoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all nk-cell lymphoma clinical trials near you to find additional studies recruiting in your area.

More Lymphoma Trials in Grand Rapids, MI

See all lymphoma clinical trials recruiting in Grand Rapids — not just this study.

Browse Lymphoma Trials in Grand Rapids →

Browse More Trials by Condition

Lymphoma TrialsPulmonary Hypertension TrialsAll Conditions →

Ready to Join in Grand Rapids?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Grand Rapids, MI